Business
Helix Biopharma Corp. Announces Issuance of U.S. Patent
(TheNewswire) (Toronto, Ontario) – TheNewswire – Helix BioPharma Corp...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix Biopharma Corp. Announces Issuance of U.S. Patent\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n (Toronto, Ontario) –\n \n\n TheNewswire –\n \n\n Helix BioPharma Corp.\n(TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”)\n(“Helix” or the “Company), a clinical-stage biopharmaceutical\ncompany developing novel and unique therapies in the field of\nimmuno-oncology, based on its proprietary technological CEACAM6\nplatform, DOS47, is pleased to announce the issuance of U.S. Patent\nNo. 11931422.\n \n\n\n\n U.S. Patent No. 11931422, entitled ‘Antibody-Urease\nConjugates for Therapeutic Purposes’, relates to Helix’\nfirst-in-class antibody-drug conjugate (ADC) platform, L-DOS47, and\nthe optimization of conjugation ratios for a proprietary antibody that\nprecisely binds to tumor cells expressing high levels of CEACAM6,\nconjugated to urease, an enzyme capable of alkalizing the acidic tumor\nmicroenvironment (TME).\n \n\n\n\n CEACAM6 is a tumor antigen highly expressed on\nhard-to-treat, prevalent cancers where currently available treatments\nare not achieving meaningful enough clinical benefits for patients\n(including non-small cell lung cancer, pancreatic and colorectal\ncancers). Binding to CEACAM6, Helix’ L-DOS47 converts urea into\nammonia and alkalizes the TME, promoting tumor regression, restoring\nfunction to local immune cells (such as T cells) and opening the\npossibility to significantly enhance the treatment outcomes of\navailable, established therapies, including chemotherapy, checkpoint\ninhibitors (immunotherapies) and targeted small molecules.\n \n\n\n\n Jacek Antas, CEO of Helix, stated: “We are very\npleased to receive the issuance of this patent in the U.S., an\nimportant oncology market with a significant need for novel treatment\nmodalities and better clinical outcomes. The timing is also\nadvantageous, considering our ongoing discussions about expanding our\npipeline with synergistic oncology products.”\n \n\n\n\n About Helix BioPharma Corp.\n \n\n\n\n Helix BioPharma Corp. is a clinical-stage\nbiopharmaceutical company developing unique therapies in the field of\nimmune-oncology for the prevention and treatment of cancer based on\nour proprietary technological platform DOS47. Helix i...